Ian E. Krop
Advertisement
Articles by Ian E. Krop
44 Results From the Phase 1/2 Study of Patritumab Deruxtecan (HER3-DXd), a HER3-Directed Antibody-Drug Conjugate (ADC), in Patients (pts) With HER3- Expressing Metastatic Breast Cancer (MBC)
ByIan E. Krop,Norikazu Masuda,Toru Mukohara,Shunji Takahashi,Takahiro Nakayama,Kenichi Inoue,Hiroji Iwata,Tatsuya Toyama,Yutaka Yamamoto,Damien Hansra,Masato Takahashi,Akihiko Osaki,Kumiko Koyama,Tatsuya Inoue,Takatoshi Yonekura,Joseph Mostillo,Shoichi Ohwada,Yoshimi Tanaka,David Sternberg,Kan Yonemori
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Obesity and Cancer Risk: The Evolving Role of GLP-1s in Oncology
2
FDA Approves Afami-cel in Metastatic Synovial Sarcoma
3
EC Approves Encorafenib/Cetuximab/FOLFOX in 1L BRAF V600E–Mutant mCRC
4
The Moonlight Shift: Dr Joshua Richter on Myeloma, Myths, and the C-Word
5